Halozyme Therapeutics (NASDAQ:HALO) Releases FY 2026 Earnings Guidance

Halozyme Therapeutics (NASDAQ:HALO) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 7.750-8.250 for the period, compared to the consensus earnings per share estimate of 7.860. The company issued revenue guidance of $1.7 billion-$1.8 billion, compared to the consensus revenue estimate of $1.7 billion. Halozyme Therapeutics also updated its FY 2025 guidance to EPS.

Halozyme Therapeutics Stock Performance

NASDAQ:HALO traded down $1.26 during mid-day trading on Friday, hitting $72.08. 303,540 shares of the company traded hands, compared to its average volume of 1,787,491. The stock’s fifty day moving average price is $68.90 and its 200-day moving average price is $68.27. The company has a quick ratio of 1.37, a current ratio of 1.59 and a debt-to-equity ratio of 1.59. Halozyme Therapeutics has a one year low of $47.50 and a one year high of $79.50. The firm has a market cap of $8.48 billion, a price-to-earnings ratio of 15.15, a price-to-earnings-growth ratio of 0.32 and a beta of 0.94.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported $1.72 EPS for the quarter, beating the consensus estimate of $1.63 by $0.09. Halozyme Therapeutics had a return on equity of 156.95% and a net margin of 47.91%.The business had revenue of $354.26 million for the quarter, compared to the consensus estimate of $339.18 million. During the same period in the previous year, the business earned $1.27 earnings per share. The business’s revenue was up 22.1% on a year-over-year basis. Research analysts anticipate that Halozyme Therapeutics will post 4.73 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently issued reports on HALO. Wall Street Zen lowered shares of Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, December 6th. Citigroup reissued a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Tuesday, November 4th. JPMorgan Chase & Co. lifted their price target on shares of Halozyme Therapeutics from $63.00 to $65.00 and gave the company a “neutral” rating in a research note on Monday, October 27th. Citizens Jmp upped their target price on Halozyme Therapeutics from $91.00 to $92.00 and gave the stock a “market outperform” rating in a report on Tuesday, November 4th. Finally, Morgan Stanley cut their price target on Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating on the stock in a research note on Monday, October 20th. Seven equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $78.80.

Insiders Place Their Bets

In related news, COO Cortney Caudill sold 4,263 shares of Halozyme Therapeutics stock in a transaction that occurred on Saturday, November 1st. The shares were sold at an average price of $65.19, for a total value of $277,904.97. Following the completion of the sale, the chief operating officer directly owned 12,737 shares in the company, valued at $830,325.03. This trade represents a 25.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Bernadette Connaughton sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $70.25, for a total transaction of $140,500.00. Following the transaction, the director owned 40,123 shares in the company, valued at $2,818,640.75. The trade was a 4.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 45,661 shares of company stock valued at $3,139,257. 2.40% of the stock is currently owned by insiders.

Key Stories Impacting Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Acquisition: Halozyme agreed to buy Surf Bio in a deal worth up to $400M, expanding its drug?delivery capabilities and complementing the ENHANZE platform — a strategic move that can drive future royalty/licensing growth. Article Title
• Positive Sentiment: Analyst support: H.C. Wainwright reiterated a Buy rating and a $90 price target, citing strength in the ENHANZE platform and Halozyme’s strategic positioning. Article Title
• Positive Sentiment: Preliminary results & guidance lift: Management reported stronger-than-expected preliminary 2025 results and raised 2026 revenue guidance into the $1.7–$1.8B range while projecting long?term royalty growth; that news pushed shares higher earlier in the week. Article Title
• Neutral Sentiment: Longer?term thesis intact: Company commentary and analyst pieces outline sustained ENHANZE momentum and projections of royalty revenue rising above $1B, supporting a multi?year growth story, but these are forward?looking and contingent on partner uptake. Article Title
• Negative Sentiment: Analyst estimate trims and a cautious outlook from some research shops: Zacks Research issued a “Hold” and made small cuts to several near?term quarterly EPS forecasts (Q2 and Q3 2026 trimmed slightly), while only marginally raising other quarter forecasts — mixed analyst movements can sap momentum after recent gains.
• Negative Sentiment: Profit?taking risk / mixed guidance signals: Despite higher revenue guidance, some investors may interpret the guidance ranges and small estimate revisions as uncertainty around near?term earnings cadence, prompting selling after a recent strong run. Article Title

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Larson Financial Group LLC boosted its stake in shares of Halozyme Therapeutics by 3,118.2% in the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 343 shares during the last quarter. Wexford Capital LP acquired a new stake in Halozyme Therapeutics during the 3rd quarter worth $70,000. Employees Retirement System of Texas raised its position in shares of Halozyme Therapeutics by 64.6% in the third quarter. Employees Retirement System of Texas now owns 1,088 shares of the biopharmaceutical company’s stock valued at $80,000 after buying an additional 427 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in shares of Halozyme Therapeutics by 6.9% in the second quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock valued at $140,000 after purchasing an additional 174 shares during the period. Finally, Acadian Asset Management LLC purchased a new stake in shares of Halozyme Therapeutics in the first quarter valued at about $195,000. 97.79% of the stock is owned by hedge funds and other institutional investors.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.